Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A phase II trial was designed to determine whether mistletoe extract can induce objective tumor response in patients with metastatic colorectal cancer resistant to 5-fluorouracil and leucovorin (5FU/LCV)-based chemotherapy. Twenty-five patients (15 female, 10 male; median age 69 yr) were treated with commercially available mistletoe extract (Abnoba-viscum Quercus) given by three weekly subcutaneous injections with daily dose gradually increased from 0.15 to 15 mg plant extract. Treatment was discontinued if unacceptable toxicity developed or if the patient became bedridden. Median duration of treatment was 14 wk (range, 4–66 wk). Treatment was continued in 14 patients until they became bedridden, and 11 patients decided to discontinue the treatment after their illness progressed. Objective tumor response was not seen in any of the 25 patients (0%, 95% confidence interval 0–13.7%). Stable disease, lasting for a median of 2.5 mo (range, 1.5–7 mo), was noted in 21 (84%) patients. Median survival was 5.5 mo and symptomatic relief was reported by 10 (40%) patients. Toxicity was mild and included mainly local inflammatory reaction. In conclusion, mistletoe extract does not seem to be active in metastatic colorectal cancer resistant to 5FU/LCV in terms of objective tumor response.
- The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10:896–903.
- De Gramont A, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18:2938–2947.
- Douillard JY, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000; 355:1041–1047. CrossRef
- Cunningham D, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352:1413–1418. CrossRef
- www.cancer.gov/cancerinfo/pdq/cam/mistletoe. Mistletoe extracts. 11/2003.
- Hutt N, et al. Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergol Immunopathol (Madr) 2001; 29:201–203.
- Paltiel O, et al. Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 2001; 19:2439–2448.
- Huber R, Barth H, Schmitt-Graff A, Klein R. Hyperesoniophilia induced by high-dose intratumoral and peritumoral mistletoe application to a patient with pancreatic carcinoma. J Alter Compl Med 2000; 6:305–310. CrossRef
- Miller AB, Hoogstraten B, Staquest M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207–214. CrossRef
- Common Toxicity Criteria. In: Investigator’s handbook: a manual for participants in clinical trials of investigational agents sponsored by the Division of Cancer Treatment, National Cancer Institute, NIH Pub. 1993; 93–2770.
- Mengs U, Gothel D, Leng-Peschlow E. Mistletoe extracts standardized to mistletoe lectins in oncology: Review on current status of preclinical research. Anticancer Res 2002; 22:1399–1407.
- Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ. Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinical applied mistletoe extract. Cancer Res 1990; 50:3322–3326.
- Heiny BM, Beuth J. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induced beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 1994; 14:1339–1342.
- Tabiasco J, Pont F, Fournie JJ, Vercellone A. Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. Eur J Biochem 2002; 269:2591–2600. CrossRef
- Mabed M, El-Helw L, Shamaa S. Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma. Br J Cancer 2004; 90:65–69. CrossRef
- Gehan EA. The determination of the number of patients in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chron Dis 1961; 13:346–353. CrossRef
- Kaegi E. Unconventional therapies for cancer: 3. Iscador. Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ 1998; 158: 1157–1159.
- Steuer-Vogt MK, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001; 37:23–31. CrossRef
- Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5-fluorouracil and leucovorin-based chemotherapy
Volume 21, Issue 3 , pp 251-254
- Cover Date
- Print ISSN
- Online ISSN
- Humana Press
- Additional Links
- Abnoba-viscum Quercus
- colorectal carcinoma
- mistletoe extract
- phase II trial
- Industry Sectors